Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

2025/04/01 by Thomas Hueso, Justin Cagnat, Kaïssa Ouali +24 · 1 voice
Medicine · Health Professions · #CAR-T cell therapy research #Safe Handling of Antineoplastic Drugs #Cancer Immunotherapy and Biomarkers

paper · doi:10.1093/cid/ciaf164

openalex publication_date 2025/04/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

We investigated infectious complications and the associated risk factors in 181 patients undergoing T-cell engagers for malignancies. Infections were primarily observed in patients with hematological diseases or heavily pre-treated. Mortality due to infectious complications was 2.8%. Concomitant medications with corticosteroids or tocilizumab did not significantly impact the incidence of infections.

Citations

• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Discussions

• Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry ✅ Just Accepted #IDSky [bsky, 4 points, 0 comments]

Related

• Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
• Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
• A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
• A review of cancer immunotherapy toxicity
• Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR)